Teva sues to head off generic Zoloft challengers

Teva Pharmaceuticals is suing several other generic drug companies that seek to challenge its position as the lone maker of non-branded Zoloft. Companies named in the suits include Novartis AG’s Sandoz and Lupin Laboratories. Zoloft (sertraline), an antidepressant marketed by Pfizer, lost patent protection in June. Teva began selling a generic version in September and has sole rights to do so until Feb. 6, the expiration date for its 180-day exclusivity period on producing sertraline. The FDA gave its tentative nod for several others to receive approval to make generic copies on that date, including Sandoz and Lupin. The Teva suits, filed in New Jersey and Delaware, target would-be sellers of generic Zoloft, plus companies that make the active ingredient, according to Bloomberg. Other companies Teva is suing are Apotex, Cipla, Cadila Healthcare's Zydus-Cadila Healthcare, Merck KGaA's Genpharm, and Watson Pharmaceuticals's Andrx, as well as manufacturers Invagen Pharmaceuticals, Hetero Drugs and Torrent Pharmaceuticals, according to court records cited by Bloomberg.
You must be a registered member of MMM to post a comment.

Next Article in Channel


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.